Twin City Private Wealth LLC Has $2.68 Million Position in Elevance Health, Inc. $ELV

Twin City Private Wealth LLC grew its position in Elevance Health, Inc. (NYSE:ELV) by 92.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,159 shares of the company’s stock after acquiring an additional 4,392 shares during the period. Elevance Health comprises about 2.0% of Twin City Private Wealth LLC’s portfolio, making the stock its 13th largest holding. Twin City Private Wealth LLC’s holdings in Elevance Health were worth $2,681,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Palouse Capital Management Inc. grew its holdings in Elevance Health by 1.8% during the first quarter. Palouse Capital Management Inc. now owns 5,493 shares of the company’s stock worth $1,608,000 after purchasing an additional 97 shares during the period. James Investment Research Inc. lifted its position in shares of Elevance Health by 84.9% in the first quarter. James Investment Research Inc. now owns 2,752 shares of the company’s stock valued at $806,000 after buying an additional 1,264 shares during the last quarter. USS Investment Management Ltd lifted its position in shares of Elevance Health by 4.7% in the first quarter. USS Investment Management Ltd now owns 37,871 shares of the company’s stock valued at $11,093,000 after buying an additional 1,689 shares during the last quarter. IFM Investors Pty Ltd boosted its stake in shares of Elevance Health by 1.9% during the 1st quarter. IFM Investors Pty Ltd now owns 48,933 shares of the company’s stock worth $14,325,000 after acquiring an additional 914 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its stake in shares of Elevance Health by 17.0% during the 1st quarter. Premier Path Wealth Partners LLC now owns 993 shares of the company’s stock worth $291,000 after acquiring an additional 144 shares during the period. 89.24% of the stock is owned by institutional investors.

Elevance Health Stock Up 7.4%

ELV stock opened at $415.51 on Thursday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $426.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The stock has a market capitalization of $90.23 billion, a price-to-earnings ratio of 17.67, a PEG ratio of 2.19 and a beta of 0.67. The business’s fifty day moving average price is $387.70 and its two-hundred day moving average price is $350.26.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the business posted $11.97 earnings per share. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were issued a $1.72 dividend. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ELV shares. UBS Group increased their price target on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Bank of America lifted their price objective on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Barclays upped their price objective on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Leerink Partners set a $364.00 target price on shares of Elevance Health in a research note on Thursday, April 23rd. Finally, Robert W. Baird lifted their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $416.11.

Insider Transactions at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares in the company, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by corporate insiders.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.